• WisBusiness

Monday, August 16, 2010

First clinical trial with embryonic stem cells based on Wisconsin research


By Tom Still
MADISON – It’s an enduring complaint about human embryonic stem cell research, often but not exclusively voiced by people opposed on moral grounds: If this research is so promising, why is it taking so long to produce treatments?

The long-term answer may emerge in a human clinical trial of a stem-cell therapy for spinal cord injuries – a therapy developed from a line of cells first cultured in Wisconsin.

Geron Corp. announced July 30 that a new drug, derived from human embryonic stem cells, has been cleared to begin clinical trials in patients stricken by acute spinal cord injuries. The trials were delayed last year by the U.S. Food and Drug Administration when one batch of mouse experiments showed cyst growth around the spinal cord injury. Additional animal trials convinced the FDA it was safe to proceed with Phase 1 trials, the first of three phases required before the drug is marketed. Those trials will begin soon in up to seven U.S. medical centers.

In addition to its potential to heal crippling spinal cord injuries in patients with fresh injuries, a dramatic result of the animal trials, Geron’s GRNOPC1 compound may eventually be tested for other applications: Alzheimer’s disease, multiple sclerosis and Canavan Disease, which can be fatal to children.

While it’s possible Geron’s drug won’t work in humans, the start of testing will likely break the logjam for other trials of drugs and therapies derived from human embryonic stem cells.

“It’s great and important news for the whole industry,” said Carl Gulbrandsen, managing director of the Wisconsin Alumni Research Foundation. After UW-Madison professor James Thomson pioneered human embryonic stem cell research, WARF obtained defining patents on that work and has since licensed federally approved stem cell lines to researchers and companies around the world – including California-based Geron.

Thomson was the first in the world to isolate human embryonic stem cells and keep them alive indefinitely in culture, a 1998 discovery the journal Science later described as one of the major milestones in the history of science.

His discovery ushered in a new era of human biological research, providing scientists with “blank slate” cells capable of becoming any of the more than 200 specialized cells in the body and offering researchers a rare view into the earliest stages of human development.

The blank-slate cells used by Geron are from WARF’s federally approved H1 line, which Gulbrandsen described as “a very, very safe line” used by researchers worldwide. The FDA go-ahead for Geron’s trials means others are now eager to sign licensing agreements with WARF, he said.

“We’ve seen another uptick in licensing activity because of (the FDA clearance for Geron),” Gulbrandsen said. “We’ve seen people who have been working for a long time in this field saying, ‘OK, let’s get this done’.”

As a result, other embryonic stem cell therapies may now move closer to clinical trials. Therapies on the horizon target diabetes, Parkinson’s disease, cardiac disease, eye disorders and even production of blood.

“Because this FDA hold has now been lifted, I suspect you’ll see more (Investigational New Drug) applications filed for human embryonic stem cell trials,” said Gulbrandsen, who credited Geron for addressing FDA’s concerns through a “a ton of hard work.”

It took 12 years to move from discovery to the first human trial. So, don’t critics have a point when they say human embryonic stem cells are largely a giant research project?

Not so, countered Gulbrandsen, who noted most non-stem cell drugs require a decade or more to move from the laboratory to the marketplace.

“This is essentially a new industry. If you look at a traditional pharmaceutical, it easily takes 10 years or more to get it approved,” he said. “This is far more complicated… it has required the development of entirely new tools and techniques.”

A successful trial using embryonic stem cells would also hasten the day when trials can begin for therapies from “induced pluripotent stem cells,” which scientists believe can perform in the same ways. Again, Wisconsin holds an edge thanks to next-generation work by Thomson and others who have reverse-engineered IPS cells without destroying embryos.

Why is it taking so long to produce therapies from human embryonic stem cell research? It’s hard scientific work and opponents haven’t made it any easier. If the Geron trials succeed, however, all that work may begin to pay off for patients and researchers alike.

-- Still is president of the Wisconsin Technology Council. He is the former associate editor of the Wisconsin State Journal in Madison.

Labels:


Comments: 4

At January 13, 2017 at 12:10 AM, Blogger bettycyoung said...

Great Please check out the adhering to tutorial for mobdro download won't be available in cost-free version. Fine.

 
At February 7, 2017 at 11:27 PM, Blogger EthelBGraff said...

good It's also incredibly versatile, with either 16GB kodidownloadapptv.com Stick presently doesn't outcome to 4K, although nice.

 
At April 23, 2017 at 1:08 AM, Blogger nancycongdon said...

System there are some vital functions readily available acmarket downloading will allow you download and install several.

 
At June 5, 2017 at 5:47 AM, Blogger dellamccabe said...

the downloaded Mobdro Apk documents from the authorities of the Mobdro Application. https://mobdroappguide.com these videos offline after saving. All the Videos as well as TV.

 

Post a Comment

Back to BizOpinion main page

: See newer blog items : : See older blog items :

BizOpinion site feed
ADVERTISEMENT
ADVERTISEMENT

wisbusiness.com Social News

Follow Us

Site Sponsors

ARCHIVE

· January 2009
· February 2009
· March 2009
· April 2009
· May 2009
· June 2009
· July 2009
· August 2009
· September 2009
· October 2009
· November 2009
· December 2009
· January 2010
· February 2010
· March 2010
· April 2010
· May 2010
· June 2010
· July 2010
· August 2010
· September 2010
· October 2010
· November 2010
· December 2010
· January 2011
· February 2011
· March 2011
· April 2011
· May 2011
· June 2011
· July 2011
· August 2011
· September 2011
· October 2011
· November 2011
· December 2011
· January 2012
· February 2012
· March 2012
· April 2012
· May 2012
· June 2012
· July 2012
· August 2012
· September 2012
· October 2012
· November 2012
· December 2012
· January 2013
· February 2013
· March 2013
· April 2013
· May 2013
· June 2013
· July 2013
· August 2013
· September 2013
· October 2013
· November 2013
· December 2013
· January 2014
· February 2014
· March 2014
· April 2014
· May 2014
· June 2014
· July 2014
· August 2014
· September 2014
· October 2014
· November 2014
· December 2014
· January 2015
· February 2015
· March 2015
· April 2015
· May 2015
· June 2015
· July 2015
· August 2015
· September 2015
· October 2015
· November 2015
· December 2015
· January 2016
· February 2016
· March 2016
· April 2016
· May 2016
· July 2016
· August 2016
· October 2016
· December 2016
Copyright ©2013 WisBusiness.com All rights reserved. | WisOpinion.com | WisPolitics.com  |  Website development by wisnet.com LLC  | Website design by Makin’ Hey Communications